Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman

Damora Therapeutics, Inc.

Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.
New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).
Peter Harwin named Chairman of the Board.
Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.